Results 101 to 110 of about 16,492 (195)

[Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2015
Hypercholesterolemia is a major risk factor for atherosclerosis. Low-density lipoprotein cholesterol (LDL-C) lowering drugs reduce cardiovascular morbidity and mortality. However, many individuals treated with statins do not achieve their target levels of LDL-C.
Ahmet, Avci, Kenan, Demir, Bülent Behlül, Altunkeser   +2 more
openaire   +1 more source

Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment. [PDF]

J Am Heart Assoc
Yu L, Xiang B, Ren Y, Li Y, Xie J, Zhou X.   +5 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9 (PCSK9) [PDF]

Science-Business eXchange, 2012
openaire   +1 more source

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. [PDF]

Circulation
Vega RB, O'Mahony G, Barbour AM, Yu H, Knöchel J, Brengdahl J, Hochdörfer T, Bergenholm L, Töppner Carlsson E, Ahnmark A, Underwood CR, Rudvik A, Carter D, Laru J, Gutgsell A, Twaddle L, Garkaviy P, Bogstedt A, Hurt-Camejo E, Miliotis T, Ryaboshapkina M, Hober A, Hubbard B, Serrano-Wu M, Kaushik V, Geschwindner S, McCarthy MC, Lindén D, Rosenmeier JB.   +28 more
europepmc   +1 more source

Proprotein convertase subtilisin kexin type 9 (PCSK9) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

Lipid-lowering drugs and essential hemorrhagic thrombocythemia's risk: A drug-target Mendelian randomization study. [PDF]

Medicine (Baltimore)
Zhang P, Wang H, Lin M, Dai P, Zhong Q, Wang R, Sheng L, He Z, Nan Z.   +8 more
europepmc   +1 more source

Therapeutic Potential of PCSK9 Inhibitors in Regulating Neuroinflammation in Acute Ischemic Stroke. [PDF]

CNS Drugs
Pu L, Liu J, Kong S, Joyama Y, Gong X, Ji X, Dong H.   +6 more
europepmc   +1 more source

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy. [PDF]

J Am Heart Assoc
Wu T, Zhao X, Xiao M, Deng J, Chen Z, Cheng D, Pan S, Liu X, Wu Y, Huang K.   +9 more
europepmc   +1 more source

Dose Up-Titration of a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Markedly Elevated Lipoprotein(a) in a Patient With Familial Hypercholesterolemia: A Case Report. [PDF]

Cureus
Suzuki N, Kishi H.
europepmc   +1 more source

PCSK9 Inhibitor Use and the Risk of Age-Related Macular Degeneration in Patients with Atherosclerotic Cardiovascular Disease. [PDF]

Pharmaceuticals (Basel)
Tsai HR, Hsu JZ, Loh CH, Huang HK.
europepmc   +1 more source